Richard Conner
Urology · Murrieta, CANPI 1275633364
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $366,860 of the $372,209 with a category attached, or 98.6%. Verathon Inc. accounts for 98.6% of it on its own, with 39 other manufacturers making up the rest. Reporting peaked in 2023 at $211,625 and has fallen 100.0% since, to $17 in 2025. Among urology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 203 payments — averaging $1833.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Verathon Inc.$367K
- Intuitive Surgical$1K
- Dendreon Pharmaceuticals LLC$658
- Johnson & Johnson$475
- AbbVie$421
- Astellas Pharma US Inc$344
- plus $2K from 34 others
What the payments were for
- Consulting fees$366,86099%
- Food & beverage$4,3871%
- Education$9630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NPD Clinical Study$366,860
- Da Vinci Surgical System$873
- UroLift$115
How this compares
$372,209 in reported general payments places this provider in the 95th percentile of 1,324 urology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 13 | $17,184 |
| Potassium Citrate ErPotassium Citrate | 11 | $1,673 |
| Tadalafil | 14 | $1,665 |
| Tamsulosin Hcl | 85 | $1,538 |
| Finasteride | 77 | $907 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $344 | $17,18413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,324 urology providers in California.
Other urology in Murrieta
- Varun TalankiMurrieta$124K
- Stephen FreedlandWest Hollywood$1.9M
- Arie BelldegrunLos Angeles$1.8M
- Mihir DesaiLos Angeles$1.5M
- Steven WilsonIndio$1.1M
- Stuart HoldenLos Angeles$1.1M
- Elward CrawfordSan Diego$849K
- Edward UchioOrange$849K
- Victor ChingUpland$809K
- Jaime LandmanOrange$657K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.